DOCSLIB.ORG

Portfolio of Investments

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Portfolio of Investments PORTFOLIO OF INVESTMENTS CTIVP® – Los Angeles Capital Large Cap Growth Fund, September 30, 2020 (Unaudited) (Percentages represent value of investments compared to net assets) Investments in securities Common Stocks 99.1% Common Stocks (continued) Issuer Shares Value ($) Issuer Shares Value ($) Communication Services 10.5% Specialty Retail 5.2% Entertainment 1.1% AutoZone, Inc.(a) 13,512 15,912,272 Activision Blizzard, Inc. 154,874 12,537,050 Home Depot, Inc. (The) 117,221 32,553,444 (a) Take-Two Interactive Software, Inc. 47,376 7,827,463 Lowe’s Companies, Inc. 152,304 25,261,141 Total 20,364,513 O’Reilly Automotive, Inc.(a) 18,198 8,390,734 Interactive Media & Services 9.3% Tractor Supply Co. 66,869 9,585,002 Alphabet, Inc., Class A(a) 26,742 39,193,075 Total 91,702,593 Alphabet, Inc., Class C(a) 26,832 39,432,307 Total Consumer Discretionary 320,972,253 (a) Facebook, Inc., Class A 319,034 83,555,005 Consumer Staples 5.0% (a) Zillow Group, Inc., Class C 10,045 1,020,472 Beverages 0.7% Total 163,200,859 Monster Beverage Corp.(a) 150,510 12,070,902 Media 0.1% Food & Staples Retailing 1.4% Cable One, Inc. 888 1,674,262 Costco Wholesale Corp. 54,693 19,416,015 Total Communication Services 185,239,634 Sprouts Farmers Market, Inc.(a) 302,524 6,331,827 Consumer Discretionary 18.2% Total 25,747,842 Automobiles 1.4% Household Products 2.9% (a) Tesla Motors, Inc. 59,240 25,414,552 Church & Dwight Co., Inc. 103,729 9,720,445 Distributors 1.7% Clorox Co. (The) 51,717 10,869,362 Pool Corp. 89,346 29,889,811 Procter & Gamble Co. (The) 216,583 30,102,871 Hotels, Restaurants & Leisure 0.2% Total 50,692,678 Domino’s Pizza, Inc. 7,735 3,289,541 Total Consumer Staples 88,511,422 Internet & Direct Marketing Retail 8.8% Financials 1.7% Amazon.com, Inc.(a) 41,309 130,070,888 Capital Markets 1.7% eBay, Inc. 101,851 5,306,437 Artisan Partners Asset Management, Inc., Class A 47,406 1,848,360 Etsy, Inc.(a) 154,980 18,850,217 MSCI, Inc. 12,798 4,566,070 Total 154,227,542 S&P Global, Inc. 62,736 22,622,602 SEI Investments Co. 6,360 322,579 Multiline Retail 0.9% Total 29,359,611 Dollar General Corp. 69,778 14,626,864 Target Corp. 11,570 1,821,350 Insurance 0.0% Total 16,448,214 Aon PLC, Class A 4,960 1,023,248 Total Financials 30,382,859 CTIVP® – Los Angeles Capital Large Cap Growth Fund | Quarterly Report 2020 1 PORTFOLIO OF INVESTMENTS (continued) CTIVP® – Los Angeles Capital Large Cap Growth Fund, September 30, 2020 (Unaudited) Common Stocks (continued) Common Stocks (continued) Issuer Shares Value ($) Issuer Shares Value ($) Health Care 11.9% Industrials 1.5% Biotechnology 1.3% Aerospace & Defense 0.1% AbbVie, Inc. 44,639 3,909,930 Lockheed Martin Corp. 3,718 1,425,035 (a) Biogen, Inc. 16,256 4,611,502 Commercial Services & Supplies 0.2% (a) Neurocrine Biosciences, Inc. 23,468 2,256,683 Cintas Corp. 9,895 3,293,353 (a) Sarepta Therapeutics, Inc. 16,943 2,379,306 Rollins, Inc. 12,340 668,705 (a) Vertex Pharmaceuticals, Inc. 38,204 10,396,072 Total 3,962,058 Total 23,553,493 Electrical Equipment 0.4% Health Care Equipment & Supplies 3.9% Rockwell Automation, Inc. 29,080 6,417,374 Abbott Laboratories 78,821 8,578,089 Machinery 0.3% Danaher Corp. 4,542 978,029 Illinois Tool Works, Inc. 29,783 5,754,373 DexCom, Inc.(a) 31,700 13,067,691 Road & Rail 0.4% Edwards Lifesciences Corp.(a) 134,808 10,760,375 Old Dominion Freight Line, Inc. 40,992 7,416,273 IDEXX Laboratories, Inc.(a) 26,330 10,350,586 Intuitive Surgical, Inc.(a) 16,566 11,754,240 Trading Companies & Distributors 0.1% ResMed, Inc. 30,112 5,162,100 Fastenal Co. 19,431 876,144 West Pharmaceutical Services, Inc. 27,642 7,598,786 Total Industrials 25,851,257 Total 68,249,896 Information Technology 49.7% Health Care Providers & Services 4.7% Communications Equipment 0.2% Anthem, Inc. 5,462 1,467,039 Cisco Systems, Inc. 99,930 3,936,243 Chemed Corp. 18,367 8,822,589 Electronic Equipment, Instruments & Components 0.2% HCA Healthcare, Inc. 31,458 3,922,183 Jabil, Inc. 111,488 3,819,579 Humana, Inc. 11,333 4,690,615 IT Services 10.9% UnitedHealth Group, Inc. 201,834 62,925,786 Accenture PLC, Class A 63,283 14,301,325 Total 81,828,212 Akamai Technologies, Inc.(a) 7,256 802,078 Health Care Technology 0.2% GoDaddy, Inc., Class A(a) 138,116 10,492,673 Veeva Systems Inc., Class A(a) 13,900 3,908,541 MasterCard, Inc., Class A 185,050 62,578,359 (a) Life Sciences Tools & Services 0.5% PayPal Holdings, Inc. 105,739 20,833,755 (a) Illumina, Inc.(a) 2,234 690,485 Square, Inc., Class A 68,369 11,113,381 Thermo Fisher Scientific, Inc. 19,093 8,429,941 Visa, Inc., Class A 354,796 70,948,556 Total 9,120,426 Total 191,070,127 Pharmaceuticals 1.3% Semiconductors & Semiconductor Equipment 9.3% (a) Eli Lilly and Co. 2,683 397,137 Advanced Micro Devices, Inc. 168,331 13,801,459 Horizon Therapeutics PLC(a) 18,591 1,444,149 Applied Materials, Inc. 153,296 9,113,447 Johnson & Johnson 99,427 14,802,692 Lam Research Corp. 18,702 6,204,388 Merck & Co., Inc. 66,206 5,491,788 Monolithic Power Systems, Inc. 15,428 4,313,823 Total 22,135,766 NVIDIA Corp. 144,668 78,297,215 Total Health Care 208,796,334 QUALCOMM, Inc. 240,544 28,307,218 2 CTIVP® – Los Angeles Capital Large Cap Growth Fund | Quarterly Report 2020 PORTFOLIO OF INVESTMENTS (continued) CTIVP® – Los Angeles Capital Large Cap Growth Fund, September 30, 2020 (Unaudited) Common Stocks (continued) Common Stocks (continued) Issuer Shares Value ($) Issuer Shares Value ($) Teradyne, Inc. 222,717 17,697,093 Materials 0.6% Texas Instruments, Inc. 42,593 6,081,854 Chemicals 0.3% Total 163,816,497 NewMarket Corp. 10,112 3,461,540 Software 17.9% Sherwin-Williams Co. (The) 3,671 2,557,732 Adobe, Inc.(a) 62,607 30,704,351 Total 6,019,272 (a) Atlassian Corp. PLC, Class A 6,396 1,162,729 Construction Materials 0.3% (a) Autodesk, Inc. 16,904 3,904,993 Eagle Materials, Inc. 54,824 4,732,408 (a) Coupa Software, Inc. 8,273 2,268,788 Total Materials 10,751,680 (a) Crowdstrike Holdings, Inc., Class A 14,333 1,968,208 Total Common Stocks Fair Isaac Corp.(a) 12,844 5,463,581 (Cost $1,166,000,853) 1,745,858,070 Fortinet, Inc.(a) 89,678 10,564,965 Money Market Funds 1.1% Intuit, Inc. 30,591 9,979,090 Shares Value ($) Manhattan Associates, Inc.(a) 8,344 796,769 Columbia Short-Term Cash Fund, 0.136%(b),(c) 19,370,509 19,368,571 Microsoft Corp. 762,556 160,388,403 Total Money Market Funds Oracle Corp. 339,212 20,250,956 (Cost $19,369,661) 19,368,571 (a) RingCentral, Inc., Class A 2,411 662,085 Total Investments in Securities Salesforce.com, Inc.(a) 23,161 5,820,822 (Cost: $1,185,370,514) 1,765,226,641 ServiceNow, Inc.(a) 57,004 27,646,940 Other Assets & Liabilities, Net (3,033,955) Workday, Inc., Class A(a) 15,885 3,417,340 Net Assets 1,762,192,686 Zoom Video Communications, Inc., Class A(a) 64,045 30,108,195 Total 315,108,215 Technology Hardware, Storage & Peripherals 11.2% Apple, Inc. 1,706,260 197,601,970 Total Information Technology 875,352,631 Notes to Portfolio of Investments (a) Non-income producing investment. (b) The rate shown is the seven-day current annualized yield at September 30, 2020. (c) As defined in the Investment Company Act of 1940, an affiliated company is one in which the Fund owns 5% or more of the company’s outstanding voting securities, or a company which is under common ownership or control with the Fund. The value of the holdings and transactions in these affiliated companies during the period ended September 30, 2020 are as follows: Net change in unrealized Beginning appreciation End of Realized gain End of Affiliated issuers of period($) Purchases($) Sales($) (depreciation)($) period($) (loss)($) Dividends($) period shares Columbia Short-Term Cash Fund, 0.136% 17,373,120 178,425,888 (176,429,950) (487) 19,368,571 1,705 83,282 19,370,509 Investments are valued using policies described in the Notes to Financial Statements in the most recent shareholder report. CTIVP® – Los Angeles Capital Large Cap Growth Fund | Quarterly Report 2020 3 3QT7033_09_K01_(09/20).
Load more

Recommended publications
  • City of Vadnais Heights Accounts Payable Printed: 08/28/2018 15:50 User:Leslee Checks by Date - Detail by Check Date Detail
    City of Vadnais Heights Accounts Payable Printed: 08/28/2018 15:50 User:leslee Checks by Date - Detail By Check Date Detail Check Amount Check No: 76626 Check Date: 08/21/2018 Vendor: ZuehlkeJ Jason J Zuehlke Bean bag tournament vendor HD 08/21/2018 200.00 Check Total: 200.00 Date Totals: 200.00 Check No: 76627 Check Date: 09/04/2018 Vendor: AspenMil Aspen Mills 221384 Uniforms - P Yang 08/23/2018 517.95 Check Total: 517.95 Check No: 76628 Check Date: 09/04/2018 Vendor: AutoData ADP, INC 520015802 PP ending 8/17/18 08/28/2018 320.17 Check Total: 320.17 Check No: 76629 Check Date: 09/04/2018 Vendor: BrowersJ John & Caitlyn Browers RefundFina Refund on overpmt of final UB 9975-0 08/23/2018 45.85 Check Total: 45.85 Check No: 76630 Check Date: 09/04/2018 Vendor: CentraPe Central Pension Fund PP ending 8/17/18 08/23/2018 200.00 Check Total: 200.00 Check No: 76631 Check Date: 09/04/2018 Vendor: CenturyL Century Link August 08/23/2018 58.36 August 08/23/2018 45.10 Check Total: 103.46 Check No: 76632 Check Date: 09/04/2018 Vendor: Cintas Cintas 4009096039 8/28/18 08/28/2018 112.38 4008882028 8/21/18 08/28/2018 110.99 Check Total: 223.37 Check No: 76633 Check Date: 09/04/2018 Vendor: CityRose City of Roseville 0224909 Aug PR1 chgs 08/28/2018 157.58 0224862 Aug Metro INET 08/28/2018 6,273.00 0224909 Aug phone support 08/28/2018 627.80 Check Total: 7,058.38 Check No: 76634 Check Date: 09/04/2018 Vendor: Comcast Comcast 8/20-9/19 8/30-9/19 cable services 08/23/2018 6.28 Check Total: 6.28 Check No: 76635 Check Date: 09/04/2018 Vendor: ComoLube Como
    [Show full text]
  • Telaprevir (Incivek)
    © Hepatitis C Online PDF created September 25, 2021, 4:19 pm Telaprevir (Incivek) Discontinued. This treatment has been discontinued. Table of Contents Telaprevir Incivek Summary Drug Summary Adverse Effects Class and Mechanism Manufacturer for United States FDA Status Indications Dosing Clinical Use Cost and Medication Access Resistance Key Drug Interactions Full Prescribing Information Figures Drug Summary Although telaprevir was a promising direct-acting antiviral agent that had impact in the hepatitis C treatment field during 2011 to 2013, it was subsequently replaced by newer direct-acting antiviral agents that were more effective, better tolerated, and more convenient. Based on the dwindling role of telaprevir after newer direct-acting antiviral agents were approved, Vertex pharmaceuticals discontinued the sales and distribution of telaprevir in the United States in October 2014. Telaprevir does have some current importance since persons who previously failed a telaprevir-based regimen may have developed resistant associated variants, which could potentially impact subsequent therapy. Adverse Effects The most significant adverse effects reported in the main registration trials and in post-marketing experience were rash, anorectal complaints, and anemia. When comparing triple therapy of telaprevir, peginterferon, and ribavirin with dual therapy of peginterferon and ribavirin alone significant differences were noted with rash (56% versus 34%), anemia (36% versus 17%), and anorectal complaints that include anorectal discomfort, anal pruritus, and hemorrhoids (29% versus 7%). In most cases, the rash that develops is eczematous or maculopapular in character and mild to moderate in severity; the rash is typically manageable with good skin care and topical emollients or corticosteroids. In some instances, however, telaprevir has caused serious skin Page 1/5 rashes, including Steven's Johnson Syndrome (SJS), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), and Toxic Epidermal Necrolysis (TEN).
    [Show full text]
  • MM .1.20 Clking
    CL King Market Maker List AAXN Axon Enterprise, Inc. CROX Crocs, Inc. HELE Helen of Troy Limited MPAA Motorcar Parts of America, Inc. SBAC SBA Communications Corporation ADBE Adobe Inc. CSCO Cisco Systems, Inc. HIBB Hibbett Sports, Inc. MRVL Marvell Technology Group Ltd. SBUX Starbucks Corporation ADSK Autodesk, Inc. CSOD Cornerstone OnDemand, Inc. HLIT Harmonic Inc. MSFT Microsoft Corporation SCVL Shoe Carnival, Inc. ADTN ADTRAN, Inc. CTAS Cintas Corporation HSIC Henry Schein, Inc. MU Micron Technology, Inc. SGMS Scientific Games Corp AGNC AGNC Investment Corp. CTSH Cognizant Technology Solutions Corporation HSII Heidrick & Struggles International, Inc. NDLS Noodles & Company SHOO Steven Madden, Ltd. AIMC Altra Industrial Motion Corp. CVLT Commvault Systems, Inc. HSKA Heska Corporation NEOG Neogen Corporation SMPL The Simply Good Foods Company ALGT Allegiant Travel Company DAKT Daktronics, Inc. HSON Hudson Global, Inc. NLOK NortonLifeLock Inc. SMRT Stein Mart, Inc. AMZN Amazon.com, Inc. DECK Deckers Outdoor Corporation IART Integra LifeSciences Holdings Corporation NTUS Natus Medical Incorporated SMSI Smith Micro Software, Inc. ANDE The Andersons, Inc. DENN Denny's Corporation ICON Iconix Brand Group, Inc. ON ON Semiconductor Corporation SNBR Sleep Number Corporation ANGO AngioDynamics, Inc. DIOD Diodes Incorporated IDXX IDEXX Laboratories, Inc. OSUR OraSure Technologies, Inc. SQBG Sequential Brands Group, Inc. ANSS ANSYS, Inc. DISCA Discovery, Inc. ILMN Illumina, Inc. Holdings PACB Pacific Biosciences of California, Inc. SRDX Surmodics, Inc. AOBC American Outdoor Brands Corporation DISH DISH Network Corporation IMBI iMedia Brands, Inc. PATK Patrick Industries, Inc. STAF Staffing 360 Solutions, Inc. AOSL Alpha and Omega Semiconductor Limited DLTR Dollar Tree, Inc. IOSP Innospec Inc. PDCO Patterson Companies, Inc.
    [Show full text]
  • ARK GENOMIC REVOLUTION MULTI SECTOR ETF (ARKG) HOLDINGS As of 09/27/2021
    ARK GENOMIC REVOLUTION MULTI SECTOR ETF (ARKG) HOLDINGS As of 09/27/2021 Company Ticker CUSIP Shares Market Value($) Weight(%) 1 TELADOC HEALTH INC TDOC 87918A105 3,937,797 531,208,815.30 6.99 2 EXACT SCIENCES CORP EXAS 30063P105 3,971,013 381,296,668.26 5.01 3 PACIFIC BIOSCIENCES OF CALIF PACB 69404D108 13,696,148 350,347,465.84 4.61 4 VERTEX PHARMACEUTICALS INC VRTX 92532F100 1,722,281 316,228,014.41 4.16 5 FATE THERAPEUTICS INC FATE 31189P102 4,825,395 312,926,865.75 4.12 6 IONIS PHARMACEUTICALS INC IONS 462222100 8,572,965 310,341,333.00 4.08 7 REGENERON PHARMACEUTICALS REGN 75886F107 430,742 275,201,063.80 3.62 8 TWIST BIOSCIENCE CORP TWST 90184D100 2,237,350 250,829,308.50 3.30 9 TAKEDA PHARMACEUTIC-SP ADR TAK UN 874060205 13,592,076 229,570,163.64 3.02 10 ACCOLADE INC ACCD 00437E102 5,268,242 226,850,500.52 2.98 11 INTELLIA THERAPEUTICS INC NTLA 45826J105 1,508,421 224,965,907.94 2.96 12 VEEVA SYSTEMS INC-CLASS A VEEV 922475108 741,198 222,307,516.14 2.92 13 CAREDX INC CDNA 14167L103 3,433,475 220,978,451.00 2.91 14 CRISPR THERAPEUTICS AG CRSP H17182108 1,804,041 210,044,493.63 2.76 15 INCYTE CORP INCY 45337C102 2,893,385 199,643,565.00 2.63 16 INVITAE CORP NVTA 46185L103 6,059,066 182,135,523.96 2.40 17 ADAPTIVE BIOTECHNOLOGIES ADPT 00650F109 4,888,391 178,377,387.59 2.35 18 BEAM THERAPEUTICS INC BEAM 07373V105 1,849,698 175,110,909.66 2.30 19 SIGNIFY HEALTH INC -CLASS A SGFY 82671G100 8,107,683 160,937,507.55 2.12 20 UIPATH INC - CLASS A PATH 90364P105 2,955,628 155,761,595.60 2.05 21 CASTLE BIOSCIENCES INC CSTL 14843C105 2,130,211
    [Show full text]
  • OSI ETF Trust O'shares U.S
    OSI ETF Trust O'Shares U.S. Quality Dividend ETF Schedule of Investments September 30, 2020 (Unaudited) Investments Shares Value ($) Investments Shares Value ($) Rockwell Automation, Inc. 4,146 914,939 COMMON STOCKS - 99.9% 1,828,788 Electronic Equipment, Instruments & Components - 0.1% Aerospace & Defense - 3.7% Amphenol Corp., Class A 6,409 693,902 General Dynamics Corp. 13,436 1,859,946 L3Harris Technologies, Inc. 4,435 753,240 Food & Staples Retailing - 2.5% Lockheed Martin Corp. 35,607 13,647,451 Costco Wholesale Corp. 15,959 5,665,445 Northrop Grumman Corp. 10,932 3,448,937 Walmart, Inc. 55,162 7,717,715 19,709,574 13,383,160 Air Freight & Logistics - 1.8% Food Products - 1.3% CH Robinson Worldwide, Inc. 9,742 995,535 General Mills, Inc. 25,291 1,559,949 Expeditors International of Hershey Co. (The) 7,961 1,141,130 Washington, Inc. 17,449 1,579,484 Hormel Foods Corp. 29,597 1,446,997 United Parcel Service, Inc., Class B 40,608 6,766,511 Kellogg Co. 8,337 538,487 9,341,530 Mondelez International, Inc., Class Banks - 0.5% A 39,472 2,267,666 JPMorgan Chase & Co. 29,156 2,806,848 6,954,229 Health Care Equipment & Supplies - 1.7% Beverages - 4.6% Abbott Laboratories 23,962 2,607,784 Brown-Forman Corp., Class B 11,255 847,727 Medtronic plc 52,777 5,484,586 Coca-Cola Co. (The) 238,082 11,754,108 Stryker Corp. 4,753 990,383 PepsiCo, Inc. 85,663 11,872,892 9,082,753 24,474,727 Health Care Providers & Services - 2.8% Biotechnology - 3.4% Anthem, Inc.
    [Show full text]
  • Vertex Pharmaceuticals Global Medical Affairs Pharmd Fellowship Program 2020 Message from Global Medical Affairs Leadership
    Vertex Pharmaceuticals Global Medical Affairs PharmD Fellowship Program 2020 Message from Global Medical Affairs Leadership Dear Candidates, Vertex Pharmaceuticals in collaboration with Northeastern University is privileged to host and expand the PharmD Fellowship Program. We are excited to work with our fellows as integral members of our team and facilitate in-depth exposure to a range of functional areas, offering them the critical opportunity to gain extensive experience in the biopharmaceutical industry. In addition to fostering each individual’s personal and professional growth, the program’s primary goal is to extend the visibility of valuable contributions that a Doctor of Pharmacy can bring to the pharmaceutical industry. At Vertex, our Global Medical Affairs fellows are highly encouraged to take on immersive projects, allowing them to work across departments with leaders in the industry. We advocate for them to partake in truly unique, impactful work that develops their skills, sparks curiosity, and drives the science. Vertex’s open and innovative culture allows the fellows to ask questions, challenge the status quo, and explore their interests across multiple expertise areas. As a pharmacist, I am extremely proud of the establishment of the Vertex PharmD Fellowship program in Global Medical Affairs and excited to welcome our future fellows. Vertex is an ideal place for fellows to start their professional career, and we are dedicated to the development of the next generation of pharmacist leaders in the biopharmaceutical industry. As Vertex continues to grow and evolve into a company in multiple disease areas, I am confident that our fellows will be an essential part of moving the needle to deliver on our commitment to patients.
    [Show full text]
  • Cornerstone 8.3 Getting Started Guide 3 Introduction
    IDEXX Cornerstone* Getting Started Guide 8.3 Proprietary Rights Notice Information in this document is subject to change without notice. Companies, names and data used in examples are fictitious unless otherwise noted. No part of this document may be reproduced or transmitted in any form or by any means, electronic, mechanical or otherwise, for any purpose, without the express written permission of IDEXX Laboratories. IDEXX Laboratories may have patents or pending patent applications, trademarks, copyrights or other intellectual or industrial property rights covering this document or subject matter in this document. The furnishing of this document does not give a license to these property rights except as expressly provided in any written license agreement from IDEXX Laboratories. © 2014 IDEXX Laboratories, Inc. All rights reserved. • 06-28486-05 *Cornerstone, IDEXX SmartOrder, IDEXX SmartService, IDEXX Monitor, IDEXX VetLab, IDEXX VetVault, Image Coach, I-Vision Mobile, LaserCyte, Patient Clipboard, Pet Health Network, SmartLink, VetConnect and VetTest are trademarks or registered trademarks of IDEXX Laboratories, Inc. or its affiliates in the United States and/or other countries. DICOM is the registered trademark of the National Electrical Manufacturers Association for its standards publications relating to digital communication of medical information. Microsoft, Hotmail, Internet Explorer, Outlook, Windows, Windows Server and Windows Vista are trademarks or registered trademarks of Microsoft Corporation in the United States and/or other countries. Accelerated Payment Technologies and XCharge are trademarks or registered trademarks of Accelerated Payment Technologies, Inc. Topaz, ClipGem, SigLite and SignatureGem are trademarks of Topaz Systems, Inc. in the U.S. and/or other countries. AMD Athlon, Opteron and Sempron are trademarks of Advanced Micro Devices, Inc.
    [Show full text]
  • Notice of 2019 Annual Meeting of Shareholders & Proxy Statement
    Notice of 2019 Annual Meeting of Shareholders & Proxy Statement Wednesday, May 8, 2019, 10:00 a.m., Eastern Time Our PURPOSE To be a great company that creates exceptional long- term value for our customers, employees and shareholders by enhancing the health and well-being of pets, people and livestock. Out Guiding Principles achieve and sustain market leadership exceed the expectations of our customers empower and reward our employees innovate with intelligence cultivate entrepreneurial spirit contribute to our communities Our Achieve and sustain market GUIDING leadership PRINCIPLES Exceed the expectations of our customers Contribute Empower and to our reward our communities employees Cultivate Innovate entrepreneurial with spirit intelligence Jonathan W. Ayers President, Chief Executive Officer and Chairman of the Board of Directors March 25, 2019 Dear Fellow Shareholders, In 2018, IDEXX delivered another year of strong growth and financial performance, sustaining our track record of creating exceptional long-term value for our customers, employees and shareholders. We are inspired by the continued pursuit of our Purpose to enhance the health and well-being of pets, people and livestock. Our Purpose We achieved outstanding financial results in 2018, with 12% revenue growth over the prior year, driven by 12% organic revenue growth, operating margin expansion of To be a great company that creates 120 basis points and growth of diluted earnings per share (“EPS”) of 45% (or exceptional long-term value for our comparable constant currency EPS growth of 36%).1 We further extended our track customers, employees and record of long-term shareholder value-creation, as reflected in the 20% compound shareholders by enhancing the annual growth rate of our stock price over the past fifteen years, and our 19% annual health and well-being of pets, total shareholder return in 2018, which again outperformed the benchmark S&P people and livestock.
    [Show full text]
  • United States Securities and Exchange Commission Form
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2005 VERTEX PHARMACEUTICALS INCORPORATED (Exact name of registrant as specified in its charter) MASSACHUSETTS 000-19319 04-3039129 (State or other jurisdiction of (Commission File Number) (IRS Employer Identification incorporation) No.) 130 Waverly Street Cambridge, Massachusetts 02139 (Address of principal executive offices) (Zip Code) (617) 444-6100 Registrant’s telephone number, including area code: Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Item 8.01. Other Events. On June 17, 2005, Vertex Pharmaceuticals Incorporated and Merck & Co., Inc. issued a joint press release that announced the initiation of an additional Phase I study with VX-680, a small molecule inhibitor of Aurora kinases. A copy of that press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Item 9.01.
    [Show full text]
  • Ensemble Capital Management Quarterly Letter
    ENSEMBLE CAPITAL MANAGEMENT QUARTERLY LETTER First Quarter 2021 The performance of securities mentioned within this letter refers to how the security performed in the market and does not reflect the performance attributed to the core equity portfolio. Please see the chart at the end of letter, which reflects the full list of contributors and detractors based on each security's weighting within the core equity portfolio. For a copy of Ensemble Capital’s equity strategy performance track record, please email a request to [email protected]. It has now been a full year since global markets were shaken by COVID. If someone fell into a deep sleep on February 19, 2020 and woke up on March 31, 2021, they’d see the S&P 500 was up 19.72% since they last checked their portfolio. By historical standards, a great return in just over thirteen months! “Not much must have happened,” they’d think, “Oh well, back to bed.” For the rest of us, we know the last year was anything but sleepy. Beyond the direct impacts of COVID, which we’ve covered in previous letters, the pandemic accelerated secular trends such as video gaming, remote working, and e-commerce. As we begin lapping those impacts, the market is wrestling with what comes next for companies that prospered or struggled during COVID. The Goldman Sachs “reopen basket,” which consists of 35 US-listed stocks that Goldman believes stand to benefit the most in a reopening scenario, was up 22.0% this quarter. In contrast, the Goldman Sachs “US Stay at Home Basket” of stocks was down 2.4%.
    [Show full text]
  • 2021 Notice of Annual Meeting of Shareholders and Proxy Statement
    2021 NOTICE OF ANNUAL MEETING OF SHAREHOLDERS AND PROXY STATEMENT Pike Place Market Store, Seattle, Washington, USA © 2021 Starbucks Corporation. To inspire and nurture the human spirit – one person, MISSION one cup and one neighborhood at a time. With our partners, our coffee and our customers at our VALUES core, we live these values: Creating a culture of warmth and belonging, where everyone is 1 welcome. Acting with courage, challenging the status quo and finding new 2 ways to grow our company and each other. Being present, connecting with transparency, dignity and respect. 3 Delivering our very best in all we do, holding ourselves accountable 4 for results. We are performance driven, through the lens of humanity. Notice of Annual Meeting of Shareholders When Where Record Date March 17, 2021, Wednesday, Via Webcast. Shareholders as of January 8, 2021 are at 10:00 a.m. (Pacific Time) www.virtualshareholdermeeting.com/ entitled to vote at the meeting SBUX2021 ITEMS OF BUSINESS BOARD VOTING PAGE REFERENCE PROPOSAL RECOMMENDATION (FOR MORE DETAIL) Management Proposals Election of 12 directors FOR each director nominee 21 Approval of an advisory resolution on our named executive officer FOR 37 compensation Ratification of selection of Deloitte & Touche LLP as our independent FOR 61 registered public accounting firm for fiscal 2021 Shareholder Proposal Employee Board Representation AGAINST 63 Shareholders will also transact such other business as may properly come before the Annual Meeting. Voting Attending the Annual Meeting Shareholders may view and listen to a live webcast of the meeting. The Your broker will not be able to vote your shares with webcast will start at 10:00 a.m.
    [Show full text]
  • Justices' Stocks, 2012-2018
    Justices' Individual Stock Ownership, 2012-2018 Legend: Bold=Stock Purchase | Italics=Stock Sale | Underline=Spinoff Chief Justice John Roberts 2012 2013 2014 2015 2016 2017 2018 1 AOL AOL AOL AOL -> Verizon Hewlett-Packard Charter Communications Charter Communications 2 Dell Hewlett-Packard Hewlett-Packard Hewlett-Packard Hillenbrand Hillenbrand Lam Research 3 Hewlett-Packard Hillenbrand Hillenbrand Hillenbrand Hill-Rom Holdings Hill-Rom Holdings Sirius XM 4 Hillenbrand Hill-Rom Holdings Hill-Rom Holdings Hill-Rom Holdings Lam Research Lam Research Texas Instruments 5 Hill-Rom Holdings Lam Research Lam Research Lam Research Microsoft Nokia Thermo Fisher Scientific 6 Intel Microsoft Microsoft Microsoft Nokia Sirius XM Time 7 Lam Research Nokia Nokia Nokia Sirius XM Texas Instruments Time Warner -> AT&T 8 Microsoft Sirius XM Sirius XM Sirius XM Texas Instruments Thermo Fisher Scientific Year-end total: 5 cos. 9 Nokia Texas Instruments Texas Instruments Texas Instruments Thermo Fisher Scientific Time 10 Sirius XM Thermo Fisher Scientific Thermo Fisher Scientific Thermo Fisher Scientific Time Time Warner 11 Texas Instruments Time Warner Time Time Time Warner Year-end total: 7 cos. 12 Thermo Fisher Scientific Time Warner Cable Time Warner Time Warner Time Warner Cable 13 Time Warner Year-end total: 12 cos. Time Warner Cable Time Warner Cable Year-end total: 9 cos. 14 Time Warner Cable Year-end total: 13 cos. Year-end total: 12 cos. Year-end total: 12 cos. Justice Stephen Breyer 2012 2013 2014 2015 2016 2017 2018 1 ADP ADP ADP ADP ADP ADP ADP 2 Air Products & Chemical Air Products & Chemical Air Products & Chemical Air Products & Chemical Air Products & Chemical Air Products & Chemical Applied Analysis 3 Amgen Applied Analysis Applied Analysis Applied Analysis Applied Analysis Applied Analysis Cintas 4 Applied Analysis BHP Billiton BHP Billiton BHP Billiton Cintas Cintas Fastenal 5 BHP Billiton Cintas CDK Global Holdings CDK Global Holdings Cisco Systems Cisco Systems Lowe's 6 Cintas Cisco Systems Cintas Cintas EMC Corp.
    [Show full text]